Overview
Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial.
Study Details
The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial is the first large prospective randomised trial to report three anti-HER2 strategies that incorporated lapatinib and trastuzumab and compared these with trastuzumab alone as adjuvant therapy for patients with early-stage HER2-positive breast cancer.
Title of Publication
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
AUTHORS
Moreno-Aspitia, A., Holmes, E.M., Jackisch, C., de Azambuja, E., Boyle, F., Hillman, D.W., Korde, L., Fumagalli, D., Izquierdo, M.A., McCullough, A.E., Wolff, A.C., Pritchard, K., Untch, M., Guillaume, S., Ewer, M. Shao, Z., Sim, S.H., Aziz, Z., Demetriou, G., Mehta, A.O., Andersson, M., Toi, M., Lang, I., Xu, B., Smith, I., Barrios, C., Baselga, J., Gelber, R.D., Piccart-Gebhart, M., Hilbers, F., El-Abed, S., Balta, V., Schurmans, C., Rosa, D.D., Saini, K., Filho, O.M., McConnell, R., Paterson, V., Campbell, C., McFadden, E., Paterson, E., and Kassab, G. for the ALTTO Steering Committee and Investigators
Publication Reference
European Journal of Cancer (EJC) | Volume 148 | Issue | Page(s) 287-296 | 2021
